Literature DB >> 30430295

Variations in the eicosapentaenoic acid-arachidonic acid ratio associated with age in acute myocardial infarction patients undergoing primary percutaneous coronary intervention.

Keisuke Nakabayashi1,2,3, Kentaro Jujo4,5, Yuho Furuki2, Issei Ishida3, Hiroshi Ando1, Minoru Shimizu1, Nobuhisa Hagiwara3, Katsumi Saito2.   

Abstract

Acute myocardial infarction (AMI) is a life-threatening disease, and its incidence has been increasing even in the young population. Although a low eicosapentaenoic acid (EPA)-arachidonic acid (AA) ratio is associated with an increased risk of coronary artery disease, the effect of age on EPA/AA ratios in AMI patients remains unclear. This study aimed to clarify the independent polyunsaturated fatty acid (PUFA)-related determinants of age in younger and older AMI patients. A total of 153 consecutive patients who underwent primary percutaneous coronary interventions (PCIs) for de novo AMIs were enrolled in this study. Patients' background data, including PUFA and lipid profiles during PCI, were evaluated retrospectively. The EPA/AA ratio correlated positively with age (r = 0.21; P = 0.011) and increased markedly from age 60 years. Patients aged < 60 years (n = 35) had a lower mean EPA/AA ratio (0.25 ± 0.16) than patients aged ≥ 60 years (n = 118) (0.38 ± 0.25) (P < 0.001). The AA level was more dependent on age than on EPA level (r = - 0.34, P < 0.001 vs. r = 0.12, P = 0.16). The multivariate analysis revealed that a 0.1 EPA/AA ratio increase (odds ratio 1.50; 95% confidence interval 1.09-2.06), body mass index, triglyceride level, and aspirin administration were independently associated with the age stratification of AMI patients. The EPA/AA ratio was higher in younger AMI patients who have undergone primary PCIs than in older patients. Younger population at risk for AMI should be managed with multiple interventions including PUFA profiling.

Entities:  

Keywords:  Acute myocardial infarction; Coronary artery disease; Eicosapentaenoic acid–arachidonic acid ratio; Percutaneous coronary intervention; Polyunsaturated fatty acids

Mesh:

Substances:

Year:  2018        PMID: 30430295     DOI: 10.1007/s00380-018-1302-6

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  38 in total

Review 1.  2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Elliott M Antman; Mary Hand; Paul W Armstrong; Eric R Bates; Lee A Green; Lakshmi K Halasyamani; Judith S Hochman; Harlan M Krumholz; Gervasio A Lamas; Charles J Mullany; David L Pearle; Michael A Sloan; Sidney C Smith; Daniel T Anbe; Frederick G Kushner; Joseph P Ornato; David L Pearle; Michael A Sloan; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; Jonathan L Halperin; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2008-01-15       Impact factor: 24.094

Review 2.  Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.

Authors:  Peter Alagona
Journal:  Am J Manag Care       Date:  2009-03       Impact factor: 2.229

3.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Hugo A Katus; Bertil Lindahl; David A Morrow; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis
Journal:  Circulation       Date:  2012-08-24       Impact factor: 29.690

Review 4.  Fibrinolytic function and coronary risk.

Authors:  I Juhan-Vague; P Morange; M Christine Alessi
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

5.  Association of serum levels of arachidonic acid and eicosapentaenoic acid with prevalence of major adverse cardiac events after acute myocardial infarction.

Authors:  Masayuki Ueeda; Takenori Doumei; Yoichi Takaya; Nobuhiko Ohnishi; Atsushi Takaishi; Satoshi Hirohata; Toru Miyoshi; Ryoko Shinohata; Shinichi Usui; Shozo Kusachi
Journal:  Heart Vessels       Date:  2010-10-21       Impact factor: 2.037

6.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

7.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

Authors:  Mitsuhiro Yokoyama; Hideki Origasa; Masunori Matsuzaki; Yuji Matsuzawa; Yasushi Saito; Yuichi Ishikawa; Shinichi Oikawa; Jun Sasaki; Hitoshi Hishida; Hiroshige Itakura; Toru Kita; Akira Kitabatake; Noriaki Nakaya; Toshiie Sakata; Kazuyuki Shimada; Kunio Shirato
Journal:  Lancet       Date:  2007-03-31       Impact factor: 79.321

Review 8.  Update on alpha-linolenic acid.

Authors:  Aliza H Stark; Michael A Crawford; Ram Reifen
Journal:  Nutr Rev       Date:  2008-06       Impact factor: 7.110

9.  Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study.

Authors:  Toshiharu Ninomiya; Masaharu Nagata; Jun Hata; Yoichiro Hirakawa; Mio Ozawa; Daigo Yoshida; Tomoyuki Ohara; Hiro Kishimoto; Naoko Mukai; Masayo Fukuhara; Takanari Kitazono; Yutaka Kiyohara
Journal:  Atherosclerosis       Date:  2013-10-05       Impact factor: 5.162

10.  Association between the docosahexaenoic acid to arachidonic acid ratio and acute coronary syndrome: a multicenter observational study.

Authors:  Yuji Nishizaki; Kazunori Shimada; Shigemasa Tani; Takayuki Ogawa; Jiro Ando; Masao Takahashi; Masato Yamamoto; Tomohiro Shinozaki; Tetsuro Miyazaki; Katsumi Miyauchi; Ken Nagao; Atsushi Hirayama; Michihiro Yoshimura; Issei Komuro; Ryozo Nagai; Hiroyuki Daida
Journal:  BMC Cardiovasc Disord       Date:  2016-07-07       Impact factor: 2.298

View more
  1 in total

1.  The Influence of Eicosapentaenoic Acid to Arachidonic Acid Ratio on Long-term Cardiovascular Events Following Percutaneous Coronary Intervention.

Authors:  Kiyoshi Niwa; Akihito Tanaka; Hiroshi Funakubo; Satoshi Otsuka; Naoki Yoshioka; Nobutaka Kudo; Akihiro Tobe; Keisuke Sakakibara; Yusuke Miki; Takashi Kataoka; Kenji Furusawa; Hideki Ishii; Toyoaki Murohara
Journal:  Intern Med       Date:  2021-06-19       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.